Imagine a tiny, smart pharmacy implanted in your body that only releases medicine when it detects a problem, like inflammation. Instead of regular injections, genetically modified friendly bacteria live inside a protective silk gel and produce the drug on the spot. These bacteria are designed to survive only inside the implant, making it safe for the patient.
Patients with chronic diseases like wet AMD suffer from the burden and side effects of repeated, lifelong injections of therapeutic proteins.
A Proof-of-Concept implantable bioreactor using silk-based hydrogels and genetically engineered bacteria that produce Anti-VEGF proteins on-demand.
If you are a clinic dealing with patients who need frequent intraocular injections for wet age-related macular degeneration — this project developed an implantable bioreactor that replaces repeated Anti-VEGF injections with a single, responsive treatment.
If you are a developer dealing with the inefficiency of systemic drug delivery for chronic inflammation — this project developed genetically engineered bacteria (GEB) that produce therapeutics on-demand based on pathological signals.
If you are a manufacturer dealing with the challenge of containing living cells in the body — this project developed silk-based hydrogels that confine and interact with bacteria at macro- and microscopic scales.
Based on available project data, there is no specific pricing or cost-per-unit information provided.
The project is currently at the Proof-of-Concept stage using in-silico tools and lab-scale silk hydrogels; industrial scaling details are not yet specified.
Based on available project data, the project has developed specific DNA sequences and logic circuits using the Cello platform, but licensing terms are not listed.
The GEB ecosystem is designed so that bacteria cannot survive outside of the encapsulating biomaterial to meet regulatory requirements.
The project period runs from 2023-12-01 to 2026-11-30, focusing on establishing the Proof-of-Concept.
The consortium is well-balanced for a translation project, consisting of 7 partners across 4 countries. With an industry ratio of 43% (including 3 industry partners and 2 SMEs), there is a strong commercial drive paired with the academic rigor of 3 universities and 1 research entity.
Contact SILK BIOMED, S.L. in Spain
Contact us to explore licensing opportunities for the GEB-silk bioreactor technology.
